Helix Biopharma Corp. Announces Strategic Board and Governance Appointments to Support Financing and Nasdaq Uplisting Strategy

Executive Summary

• Helix BioPharma has appointed Zachary T. Stadnyk to its Board of Directors.
• Natalia L. Butterworth has been appointed as the Company's Corporate Secretary.
• The Company is in the process of relocating its registered and records office from Toronto, Ontario, to Vancouver, British Columbia.

Key Details

• Board Appointment: Zachary T. Stadnyk, former TSX Life Sciences Lead, joins the Board; he brings experience in biotechnology capital markets, having supported over $100 million in institutional financings.
• Corporate Secretary Appointment: Natalia L. Butterworth, from ARO Consulting Inc., joins as Corporate Secretary, bringing over 15 years of corporate governance and regulatory compliance experience.
• Strategic Objective: These appointments and the office relocation are intended to strengthen capital markets and governance infrastructure as the Company prepares for a planned Nasdaq listing through the Multijurisdictional Disclosure System (MJDS).
• Operational Context: The changes coincide with the finalization of the clinical protocol for L-DOS47.

Notable Quotes

"As Helix continues to execute on its corporate and clinical development objectives, strengthening our capital markets and governance capabilities remains a key priority. [...] These appointments come at an important time for Helix as we finalize the clinical protocol for L-DOS47 and actively prepare for a Nasdaq listing under the MJDS, including ongoing audit, governance, and capital markets readiness initiatives." — Thomas Mehrling, MD, PhD, Chief Executive Officer